Congress presentation: ISGE 2026 Safety and tolerability of elinzanetant: pooled analysis from multiple clinical trials

Bayer AG 2026 Open access

Read full text
Authors: Rossella Elena Nappi, James A. Simon, Claudio N. Soares, Nick Panay, Christiane Ahlers, Maja Francuski, Kelly Genga, Cecilia Caetano, Senka Djordjevic, Christian Seitz
DOI: 10.71943/bayer.figshare.31211197
Cited by: 0

Abstract

Elinzanetant was well-tolerated over 52 weeks, with low incidence of TEAEs and discontinuations. No concerning safety signals in hepatic, endometrial, metabolic, or bone parameters emerged. The most common TEAEs, headache and fatigue, were mild-to-moderate and mostly transient, supporting elinzanetant’s potential as a long-term dual neurokinin-targeted therapy for menopausal symptoms

Fields of Study & Subjects

Menopause: Health Impacts and Treatments Pharmacovigilance and Adverse Drug Reactions Reproductive Health and Contraception

Publication details

Journal / source
Bayer AG
Publication date
6 March 2026
Language
EN